0000905148-26-001867.txt : 20260427 0000905148-26-001867.hdr.sgml : 20260427 20260427162853 ACCESSION NUMBER: 0000905148-26-001867 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260423 FILED AS OF DATE: 20260427 DATE AS OF CHANGE: 20260427 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: YERXA BENJAMIN R CENTRAL INDEX KEY: 0001145910 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34079 FILM NUMBER: 26901435 MAIL ADDRESS: STREET 1: INSPIRE PHARMACEUTICALS, INC., STREET 2: 4222 EMPEROR BLVD., STE. 470 CITY: DURHAM STATE: NC ZIP: 27703-8466 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Opus Genetics, Inc. CENTRAL INDEX KEY: 0001228627 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 113516358 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8 DAVIS DRIVE STREET 2: SUITE 220 CITY: DURHAM STATE: NC ZIP: 27713 BUSINESS PHONE: 248-681-9815 MAIL ADDRESS: STREET 1: 8 DAVIS DRIVE STREET 2: SUITE 220 CITY: DURHAM STATE: NC ZIP: 27713 FORMER COMPANY: FORMER CONFORMED NAME: Ocuphire Pharma, Inc. DATE OF NAME CHANGE: 20201109 FORMER COMPANY: FORMER CONFORMED NAME: REXAHN PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20050516 FORMER COMPANY: FORMER CONFORMED NAME: CORPORATE ROAD SHOW DOT COM INC DATE OF NAME CHANGE: 20030423 4 1 form4.xml FORM 4 X0609 4 2026-04-23 0001228627 Opus Genetics, Inc. IRD 0001145910 YERXA BENJAMIN R false C/O OPUS GENETICS, INC. 8 DAVIS DRIVE, SUITE 220 DURHAM NC 27713 true true false false President false Common Stock 2026-04-23 4 S false 7470 5.2371 D 711535 D The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person. The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.2314 to $5.2413, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Amy Rabourn, by Power of Attorney 2026-04-27